Table 3.
Association of RBCT and postoperative outcomes following gastrectomy for gastric cancer
| Outcome | Unadjusted | Adjusted* | ||
|---|---|---|---|---|
|
|
|
|||
| RR (95% CI) | p value | RR (95%CI) | p value | |
| Major morbidity | 1.95 (1.68–2.26) | < 0.001 | 1.44 (1.18–1.76) | < 0.001 |
|
| ||||
| Mortality | 3.83 (2.55–5.75) | < 0.001 | 3.06 (1.89–4.95) | < 0.001 |
|
| ||||
| Postoperative infections | 1.81 (1.55–2.12) | < 0.001 | 1.35 (1.14–1.61) | < 0.001 |
|
| ||||
| Cardiac events | 2.41 (1.44–4.03) | < 0.001 | 1.77 (0.97–3.23) | 0.06 |
|
| ||||
| Respiratory failure | 3.02 (2.23–4.08) | < 0.001 | 2.34 (1.64–3.34) | < 0.001 |
|
| ||||
| Venous thromboembolic events | 1.63 (0.94–2.83) | 0.08 | 1.14 (0.61–2.12) | 0.69 |
|
| ||||
| Reoperation | 1.91 (1.40–2.62) | < 0.001 | 1.59 (1.11–2.28) | 0.011 |
|
| ||||
| Length of stay | 1.36 (1.28–1.44) | < 0.001 | 1.15 (1.08–1.22) | < 0.001 |
CI = confidence interval; RBCT = red blood cell transfusion; RR = relative risk.
*
Adjusted for: age, sex, race, body mass index, American Society of Anesthesiologists class, hematocrit, bilirubin, international normalized ratio, cardiac comorbidities, bleeding disorder, primary operation, multivisceral resection and operative duration.